Patterns of Use of Docetaxel-Containing Adjuvant Chemotherapy Among Chinese Patients with Operable Breast Cancer: A Multicenter Observational Study-Reference-Cited by-同舟云学术

Patterns of Use of Docetaxel-Containing Adjuvant Chemotherapy Among Chinese Patients with Operable Breast Cancer: A Multicenter Observational Study

Published:2018-12-03 Issue:1 Volume:36 Page:131-146
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Xie Hui,Liu Jinping,Yu Shiyou,Chen Yiding,Zheng Min,Deng Yongchuan,Wang Shu,Jiang Jun,Li Yafen,Li Huiping,Kang Hua,Zhang Chunhui,Zhang Guo-Jun,Su Fengxi,Cheng Aiqun,Wang Shui^ORCID

Funder

Sanofi China Investment Company

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/article/10.1007/s12325-018-0841-7/fulltext.html

Reference50 articles.

1. Chow LW, Biganzoli L, Leo AD, et al. Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients. Asia Pac J Clin Oncol. 2017. https://doi.org/10.1111/ajco.12682 .

2. Li J, Zhang BN, Fan JH, et al. A nation-wide multicenter 10-year (1999–2008) retrospective clinical epidemiological study of female breast cancer in China. BMC Cancer. 2011;11:364. https://doi.org/10.1186/1471-2407-11-364 .

3. Anampa J, Makower D, Sparano JA. Progress in adjuvant chemotherapy for breast cancer: an overview. BMC Med. 2015;13:195. https://doi.org/10.1186/s12916-015-0439-8 .

4. Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v8–30. https://doi.org/10.1093/annonc/mdv298 .

5. Gradishar WJ, Anderson BO, Balassanian R, et al. NCCN guidelines insights: breast cancer, version 1.2017. J Natl Compr Cancer Netw. 2017;15(4):433–51.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Angelica sinensis polysaccharide suppresses the Wnt/β-catenin-mediated malignant biological behaviors of breast cancer cells via the miR-3187-3p/PCDH10 axis;Biochemical Pharmacology;2024-07

2. The Pretreatment Systemic Inflammation Response Index as a Useful Prognostic Factor is Better Than Lymphocyte to Monocyte Ratio in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy;Clinical Breast Cancer;2022-07

3. Systemic Immune-Inflammation Index Is Superior to Neutrophil to Lymphocyte Ratio in Prognostic Assessment of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy;BioMed Research International;2020-12-18

4. Sales of anti-cancer medicines; China, Indonesia, Kazakhstan, Malaysia, Philippines and Thailand;Bulletin of the World Health Organization;2020-05-28

5. Pre‐treatment systemic immune‐inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy;Journal of Cellular and Molecular Medicine;2020-01-27